Full Press Release Details
IDEAYA Biosciences Announces Selection of Move Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP Deletion Squamous Non Small Cell Lung Cancer.
IDYA
IDEAYA Biosciences Announces Selection of Move Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP Deletion Squamous Non Small Cell Lung Cancer
Key Takeaway: IDEAYA Biosciences Announces Selection of Move Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP Deletion Squamous Non Small Cell Lung Cancer